Yes, certain chemotherapeutic agents and other medications have been associated with therapy-related MDS (t-MDS). Alkylating agents and topoisomerase II inhibitors are known to cause mutagenesis in hematopoietic stem cells, which can lead to MDS as a secondary malignancy. Patients who have undergone chemotherapy for other cancers are at an increased risk for developing t-MDS.
